Cantor Fitzgerald Reiterates Overweight Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports.

EOLS has been the subject of a number of other research reports. Barclays boosted their target price on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, August 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Friday, September 13th.

Evolus Stock Up 0.7 %

EOLS opened at $16.89 on Monday. Evolus has a fifty-two week low of $7.44 and a fifty-two week high of $17.70. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. The company has a fifty day moving average of $13.87 and a two-hundred day moving average of $13.06. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -16.09 and a beta of 1.30.

Evolus (NASDAQ:EOLS) last released its earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to analyst estimates of $65.06 million. On average, research analysts expect that Evolus will post -0.64 earnings per share for the current year.

Insider Buying and Selling at Evolus

In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares in the company, valued at approximately $1,305,643.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Evolus

Large investors have recently made changes to their positions in the stock. Quest Partners LLC purchased a new position in shares of Evolus in the 2nd quarter valued at about $43,000. Quarry LP purchased a new position in Evolus during the 2nd quarter valued at about $54,000. Tradition Wealth Management LLC increased its holdings in Evolus by 44.8% during the 4th quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock valued at $84,000 after acquiring an additional 2,475 shares in the last quarter. Sierra Summit Advisors LLC purchased a new position in Evolus during the 4th quarter valued at about $119,000. Finally, Profund Advisors LLC purchased a new position in Evolus during the 2nd quarter valued at about $130,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.